Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP795721.RApq-0gQ_bbQuYlKFGiIvuvDMnALXK-uyEMgXEqO92LA8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP795721.RApq-0gQ_bbQuYlKFGiIvuvDMnALXK-uyEMgXEqO92LA8130_assertion type Assertion NP795721.RApq-0gQ_bbQuYlKFGiIvuvDMnALXK-uyEMgXEqO92LA8130_head.
- NP795721.RApq-0gQ_bbQuYlKFGiIvuvDMnALXK-uyEMgXEqO92LA8130_assertion description "[Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP795721.RApq-0gQ_bbQuYlKFGiIvuvDMnALXK-uyEMgXEqO92LA8130_provenance.
- NP795721.RApq-0gQ_bbQuYlKFGiIvuvDMnALXK-uyEMgXEqO92LA8130_assertion evidence source_evidence_literature NP795721.RApq-0gQ_bbQuYlKFGiIvuvDMnALXK-uyEMgXEqO92LA8130_provenance.
- NP795721.RApq-0gQ_bbQuYlKFGiIvuvDMnALXK-uyEMgXEqO92LA8130_assertion SIO_000772 20179708 NP795721.RApq-0gQ_bbQuYlKFGiIvuvDMnALXK-uyEMgXEqO92LA8130_provenance.
- NP795721.RApq-0gQ_bbQuYlKFGiIvuvDMnALXK-uyEMgXEqO92LA8130_assertion wasDerivedFrom befree-2016 NP795721.RApq-0gQ_bbQuYlKFGiIvuvDMnALXK-uyEMgXEqO92LA8130_provenance.
- NP795721.RApq-0gQ_bbQuYlKFGiIvuvDMnALXK-uyEMgXEqO92LA8130_assertion wasGeneratedBy ECO_0000203 NP795721.RApq-0gQ_bbQuYlKFGiIvuvDMnALXK-uyEMgXEqO92LA8130_provenance.